Polaryx Therapeutics (PLYX)
Market Price (3/30/2026): $7.63 | Market Cap: $361.2 MilSector: Health Care | Industry: Biotechnology
Polaryx Therapeutics (PLYX)
Market Price (3/30/2026): $7.63Market Cap: $361.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Rare Disease Therapeutics, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -140% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.8 Mil | ||
| High stock price volatilityVol 12M is 375% | ||
| Key risksPLYX key risks include [1] its critical dependence on successful clinical trial outcomes and regulatory approvals, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Rare Disease Therapeutics, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -140% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.8 Mil |
| High stock price volatilityVol 12M is 375% |
| Key risksPLYX key risks include [1] its critical dependence on successful clinical trial outcomes and regulatory approvals, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Polaryx Therapeutics (PLYX) stock has lost about 80% since it went public on 2/2/2026 because of the following key factors:
1. Significant Initial Overvaluation and Subsequent Price Correction Post-Direct Listing.
Polaryx Therapeutics (PLYX) began trading on Nasdaq via a direct listing on February 2, 2026, with shares opening as high as $45.00 and reaching an intraday high of $48.91 on its debut day. However, the stock closed at $35.00 on the first day of trading. This initial trading price was substantially higher than the average price of $2.51 per share at which existing shares were issued to investors in September 2025. The dramatic disparity between the private sale price and the high direct listing price suggests a significant overvaluation by the market in the immediate aftermath of the listing, leading to an almost immediate and drastic correction as the stock has since fallen to a range of $6.38 - $7.79 by late March 2026.
2. Inherent Risks and Lack of Revenue for a Clinical-Stage Biotechnology Company.
Polaryx Therapeutics operates as a clinical-stage biotechnology company focused on developing therapies for rare pediatric lysosomal storage disorders. As of its direct listing and up to the present, the company generates no revenue from product sales and reported a net loss of $8.99 million for the full year ended December 31, 2025. Companies at this early stage are inherently high-risk, with their valuation heavily dependent on the uncertain outcomes of future clinical trials and regulatory approvals. This speculative nature, combined with a lack of current earnings, contributes to significant stock price volatility and a struggle to maintain sustained investor confidence following any initial speculative interest.
Show more
1. Significant Initial Overvaluation and Subsequent Price Correction Post-Direct Listing.
Polaryx Therapeutics (PLYX) began trading on Nasdaq via a direct listing on February 2, 2026, with shares opening as high as $45.00 and reaching an intraday high of $48.91 on its debut day. However, the stock closed at $35.00 on the first day of trading. This initial trading price was substantially higher than the average price of $2.51 per share at which existing shares were issued to investors in September 2025. The dramatic disparity between the private sale price and the high direct listing price suggests a significant overvaluation by the market in the immediate aftermath of the listing, leading to an almost immediate and drastic correction as the stock has since fallen to a range of $6.38 - $7.79 by late March 2026.
2. Inherent Risks and Lack of Revenue for a Clinical-Stage Biotechnology Company.
Polaryx Therapeutics operates as a clinical-stage biotechnology company focused on developing therapies for rare pediatric lysosomal storage disorders. As of its direct listing and up to the present, the company generates no revenue from product sales and reported a net loss of $8.99 million for the full year ended December 31, 2025. Companies at this early stage are inherently high-risk, with their valuation heavily dependent on the uncertain outcomes of future clinical trials and regulatory approvals. This speculative nature, combined with a lack of current earnings, contributes to significant stock price volatility and a struggle to maintain sustained investor confidence following any initial speculative interest.
Show more
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PLYX | ||
| Market (SPY) | -5.3% | -0.4% |
| Sector (XLV) | -8.7% | -8.7% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PLYX | ||
| Market (SPY) | 0.6% | -0.4% |
| Sector (XLV) | 5.2% | -8.7% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PLYX | ||
| Market (SPY) | 9.8% | -0.4% |
| Sector (XLV) | -2.1% | -8.7% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PLYX | ||
| Market (SPY) | 69.4% | -0.4% |
| Sector (XLV) | 18.4% | -8.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PLYX Return | - | - | - | - | - | -82% | -82% |
| Peers Return | 801% | -19% | 2% | -20% | 23% | -5% | 601% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| PLYX Win Rate | - | - | - | - | - | 50% | |
| Peers Win Rate | 48% | 43% | 43% | 47% | 57% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| PLYX Max Drawdown | - | - | - | - | - | -93% | |
| Peers Max Drawdown | -33% | -43% | -28% | -39% | -32% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BMRN, FOLD, DNLI, RGNX, ZVRA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
PLYX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to BMRN, FOLD, DNLI, RGNX, ZVRA
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Polaryx Therapeutics (PLYX)
We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our small molecule drug candidates share target indications, as well as similar modes of action, that have been demonstrated to address lysosomal dysfunction, neuroinflammation, and neuronal loss in our validated animal models that closely mimic human clinical phenotypes. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch a Phase 2 proof-of-concept basket trial which may enhance PLX-200’s potential to become the standard of care across multiple LSDs. Our drug candidate pipeline includes: • PLX-200 (gemfibrozil), our most advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that we are pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. We are advancing PLX-200 through a Phase 2 proof-of-concept basket trial, which we refer to as SOTERIA (PLX-200-600), and expect to initiate this trial in the first half of 2026. SOTERIA is an open-label, multi-indication, master study for the treatment of certain LSDs, which we believe represent approximately one quarter of the LSD population, including Classic Late Infantile Neuronal Ceroid Lipofuscinosis (“CLN2”), and Juvenile Neuronal Ceroid Lipofuscinosis (“CLN3”) subtypes of neuronal ceroid lipofuscinosis (“NCL”), Krabbe disease, and Sandhoff disease. We have held a pre-investigational new drug (“IND”) submission meeting with the U.S. Food and Drug Administration (“FDA”). We submitted an IND application to the FDA for the SOTERIA trial in August 2025 and received a safe to proceed letter in October 2025. • Data readouts from SOTERIA are expected to provide guidance and a clear pathway for each of the four indications towards potentially registrable trials. We believe there may also be an opportunity to seek accelerated approval for CLN2 and CLN3 from the FDA based on precedent approval for a third-party drug with a similar trial design. Products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. • PLX-200 has already received authorization under two separate INDs to initiate potentially single pivotal trials in CLN2 and CLN3, the most prevalent subtypes of NCLs, which we filed on December 20, 2019 and March 6, 2020 and received authorization for on January 17, 2020 and April 6, 2020. Initiation of these trials was delayed due to the COVID-19 pandemic and a subsequent shift in our strategy. We currently do not expect to commence the trials in the near term while we focus our resources on SOTERIA. To date, the FDA has granted three orphan drug designations (“ODD”) to PLX-200, for the treatment of all 13 subtypes of NCLs, GM2 gangliosidoses, such as Tay-Sachs and Sandhoff diseases, and Krabbe disease. PLX-200 has also received fast track (“Fast Track”) designation for the treatment of CLN3. The receipt of such designations does not guarantee a faster development process, regulatory review, or approval as compared to the conventional FDA approval process. • PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. To date, the FDA has granted three ODDs to PLX-300 for the treatment of GM2 gangliosidosis, Krabbe disease, and Niemann-Pick Disease (“NPD”) type A and type B. PLX-300 has also received rare pediatric drug designation (“RPD”) for the treatment of GM2 gangliosidosis, Krabbe disease, and NPD type A and type B. The receipt of such designations does not guarantee a faster development process, regulatory review, or approval as compared to the conventional FDA approval process. • PLX-100 is a preclinical stage orally administrable combination therapy comprised of our PPARα agonist, PLX-200, and vitamin A, a retinoid X receptor alpha (“RXRα”) agonist. PLX-100 is being developed for the treatment of LSDs. To date, the FDA has granted one ODD to PLX-100 for the treatment of classic late infantile neuronal ceroid lipofuscinoses, or CLN2. The receipt of such designation does not guarantee a faster development process, regulatory review, or approval as compared to the conventional FDA approval process. • PLX-400 is a preclinical stage novel gene therapy being developed for the treatment of LSDs. We are exploring PLX-400 as a monotherapy or in combination with oral administration of PLX-200 and expect to determine any clinical development plans for PLX-400 at a later date. LSDs are a heterogeneous group of nearly 50 inherited rare, catastrophic, metabolic diseases caused by mutations in genes encoding lysosomal enzymes or associated proteins. These mutations result in the accumulation of undegraded substrates within lysosomes, leading to cellular dysfunction, chronic inflammation, and cell apoptosis. LSDs often manifest in infancy or early childhood and are associated with severe clinical outcomes, including developmental regression, seizures, blindness, motor impairment, and premature death. We believe that there are approximately 50,000 LSD patients in the United States, Europe and select regions of the rest of the world (“ROW”), assuming an incidence rate of one in 5,000 births. The LSDs addressed by our pipeline of drug candidates are currently treated for symptomatic relief and palliative care, and, with few exceptions, lack approved disease-modifying therapies. Our drug candidates have been validated in gold standard preclinical animal models for CLN2, CLN3, Sandhoff disease, Krabbe disease and NPD type A and type B. With similar broad disease pathology shared across multiple LSDs in terms of substrate accumulation, neuroinflammation, and neuronal loss, we believe our small molecule drug candidates have the potential to demonstrate high therapeutic benefit in other targeted indications. Our development program is focused on a subset of rare LSDs with particularly high unmet need, including: • Neuronal Ceroid Lipofuscinoses: A group of 13 genetically distinct subtypes categorized according to the associated gene (CLN1 – 8; CLN10 – 14), we believe that NCLs represent approximately 15% of the LSD population, roughly 7,700 patients in the United States, Europe and select regions of ROW. NCLs are characterized by progressive neurodegeneration, vision loss, and early mortality. The three most common forms of NCLs are CLN1, CLN2, and CLN3. Of the 13 NCL sub-types, only one, CLN2, has an established standard of care in the form of an enzyme replacement therapy. • Krabbe Disease: Krabbe disease, also known as globoid cell leukodystrophy, is caused by mutations in the galactosylceramidase (“GALC”) gene, leading to galactocerebrosidase deficiency and an inability to break down certain lipids in the body. This results in accumulation of toxic substances in the brain and other areas of the nervous system leading to demyelination and severe neurological decline. The incidence rate of Krabbe disease varies significantly, affecting 0.3 to 2.6 per 100,000 live births. We believe that there are approximately 6,700 Krabbe disease patients in the United States, Europe and select regions of the ROW. Hematopoietic stem cell transplantation (“HSCT”) is considered the current standard of care. • Tay-Sachs and Sandhoff Diseases: Tay-Sachs and Sandhoff Diseases are part of a group of inherited disorders called GM2 gangliosidoses, resulting from deficiencies in the hexosaminidase enzyme. This mutation leads to an accumulation of GM2 ganglioside in nerve cells, resulting in rapid neurodegeneration. While the prevalence of Tay-Sachs disease is approximately one in 100,000 births, Sandhoff Disease is much rarer with a prevalence of approximately 0.67 per 100,000 births. We believe that there are approximately 1,200 Sandhoff disease patients in the United States, Europe and select regions of the ROW. There is currently no established standard of care for these diseases. • Niemann-Pick Disease Types A and B: NPD is caused by mutations in the sphingomyelin phosphodiesterase 1 (“SMPD1”) gene. This causes acid sphingomyelinase enzyme deficiency, leading to lipid accumulation in multiple organs, including the brain. The prevalence for NPD types A and B is one in 250,000 births, with a high prevalence found within the Ashkenazi Jewish population. An enzyme replacement therapy has been approved for the treatment of NPD type A and type B, but is not intended to treat neurological symptoms. Our principal executive offices are located in Paramus, New Jersey.
AI Analysis | Feedback
An early-stage Alexion Pharmaceuticals, specializing in novel therapies for rare pediatric lysosomal storage disorders.
Like a nascent Sarepta Therapeutics, focused on developing innovative treatments for multiple rare, devastating pediatric genetic disorders.
AI Analysis | Feedback
- PLX-200 (gemfibrozil): An oral small molecule, repurposed drug advancing through a Phase 2 basket trial (SOTERIA) for various lysosomal storage disorders (LSDs) like CLN2, CLN3, Krabbe, and Sandhoff diseases.
- PLX-300 (cinnamic acid): A novel, oral small molecule therapy in IND-enabling studies for LSDs, including GM2 gangliosidosis, Krabbe disease, and Niemann-Pick Disease types A and B.
- PLX-100: A preclinical stage orally administrable combination therapy comprising PLX-200 and vitamin A, being developed for LSDs, specifically CLN2.
- PLX-400: A preclinical stage novel gene therapy being explored for the treatment of LSDs, potentially as a monotherapy or in combination with PLX-200.
AI Analysis | Feedback
Polaryx Therapeutics (PLYX) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for rare, pediatric lysosomal storage disorders. As a clinical-stage company, Polaryx Therapeutics does not currently have major customers or categories of customers, as its drug candidates are still in various stages of clinical trials (Phase 2, IND-enabling, and preclinical) and have not yet received regulatory approval for commercial sale. Therefore, the company is not currently generating revenue from product sales.
AI Analysis | Feedback
nullAI Analysis | Feedback
Alex Yang, J.D., LL.M. - CEO and Chair of the Board
Alex Yang has served as Chair of the Board since June 2021 and Chief Executive Officer since March 2023. He is also the CEO and founder of Mstone Partners. Since 2016, he has served in senior management and chair of board roles for several biopharmaceutical companies. With over 25 years of experience, he has advised and executed fund formation, cross-border transactions, and a diverse range of investment experiences across multiple industry sectors. He currently serves on investment and risk committees for various regional and country-focused private equity funds. Prior roles include managing partner at Kim & Chang and partner at Ernst & Young Hong Kong, where he led regional financial services practice. He also worked at Morgan Stanley Hong Kong Office in Asia Private Equity and In-house Counsel, focusing on buy-outs, grow-capital investments, real estate, special situations, and infrastructure transactions across Asia.
G. Michael Landis, CPA - Chief Financial Officer and Director
G. Michael Landis is an accomplished financial executive with over 25 years of experience in public company expertise, capital market transactions, investor relations, and financial reporting. Immediately prior to joining Polaryx, he was Chief Financial Officer at Epygenix Therapeutics, a late-stage clinical biopharmaceutical company that was acquired in April 2024. He also served as Chief Financial Officer at Avisa Diagnostics Inc., a publicly traded medical device company, where he was responsible for strategic and tactical finance initiatives, investor relations, and capital-raising activities. He also served as Principal Accounting Officer and Treasurer at Lannett Company Inc., a publicly traded pharmaceutical company.
Dr. Lisa L. Bollinger, M.D. - Chief Medical Officer
Dr. Lisa Bollinger is a board-certified pediatrician with over 30 years of experience in drug development, possessing deep expertise in regulatory affairs and clinical safety. Before joining Polaryx, she founded Bollinger Regulatory Consulting (BRC), where she provided regulatory and clinical expertise to venture capital firms. Her previous roles include Vice President of Regulatory Affairs at Merck Sharp & Dohme and senior positions at Amgen.
Eddy Zhu, Ph.D., PMP - Chief CMC Officer
Eddy Zhu is a highly accomplished scientific professional, specializing in chemistry, manufacturing, and controls (CMC) management with over 20 years of experience in commercial manufacturing, pharmaceutical development, and regulatory approvals. He has a proven track record of success as a leader in technical R&D excellence in both multinational corporation (MNC) and small startup environments, resulting in numerous peer-reviewed publications and several formulation patents. Prior to Polaryx, he served as Product Development Lead at Sanofi, playing a critical role in pharmaceutical and non-pharmaceutical formulation and development across oral solids, liquids, and injectables.
Dr. Shrijay Vijayan, Ph.D. - Chief Scientific and Business Development Officer
Dr. Shrijay Vijayan is a highly experienced biomedical technology commercialization executive with an extensive industry network and more than 20 years of technical expertise.
AI Analysis | Feedback
The key risks for Polaryx Therapeutics (PLYX) are primarily centered around its status as a clinical-stage biotechnology company developing treatments for rare diseases.
- Clinical Trial Success and Regulatory Approval: As a clinical-stage company, the paramount risk for Polaryx Therapeutics is the successful outcome of its ongoing and planned clinical trials, particularly the Phase 2 SOTERIA basket trial for its most advanced candidate, PLX-200. The company's future development pathway for its multiple indications is explicitly dependent on data readouts from SOTERIA. Even with positive trial results, obtaining regulatory approval from the U.S. Food and Drug Administration (FDA) is not guaranteed, despite receiving designations like Orphan Drug and Fast Track, which the company states "does not guarantee a faster development process, regulatory review, or approval". The background also notes previous delays in initiating trials due to the COVID-19 pandemic and a subsequent shift in strategy, highlighting the potential for further delays.
- Competition from Existing Therapies and Standards of Care: For some of the rare lysosomal storage disorders (LSDs) that Polaryx Therapeutics targets, existing treatments or established standards of care are already available. For instance, CLN2, one of the NCL subtypes, has an established enzyme replacement therapy. Krabbe disease has hematopoietic stem cell transplantation (HSCT) as the current standard of care. Additionally, an enzyme replacement therapy has been approved for Niemann-Pick Disease (NPD) types A and B, although it does not treat neurological symptoms. Polaryx's drug candidates will need to demonstrate clear advantages in efficacy, safety, or patient convenience to compete effectively with these established options and gain market adoption.
- Dependence on a Limited Pipeline of Advanced Drug Candidates: While Polaryx Therapeutics has a pipeline of drug candidates, including PLX-200, PLX-300, PLX-100, and PLX-400, the company's immediate strategy and resource allocation are heavily focused on the PLX-200 program, particularly the SOTERIA trial. The company has explicitly stated that it does not expect to commence previously authorized pivotal trials for CLN2 and CLN3 in the near term, opting instead to focus resources on SOTERIA. A significant setback or failure in the development of PLX-200 could therefore have a disproportionately large impact on the company's overall prospects and valuation.
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlFor Polaryx Therapeutics (PLYX), the addressable markets for their main products, which target various Lysosomal Storage Disorders (LSDs), are as follows:
- Neuronal Ceroid Lipofuscinoses (NCLs): Approximately 7,700 patients in the United States, Europe, and select regions of the rest of the world (ROW).
- Krabbe Disease: Approximately 6,700 patients in the United States, Europe, and select regions of the ROW.
- Sandhoff Disease (a type of GM2 gangliosidosis): Approximately 1,200 patients in the United States, Europe, and select regions of the ROW.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Polaryx Therapeutics (PLYX) over the next 2-3 years:
- Accelerated Approval and Commercialization of PLX-200 for CLN2 and CLN3: Polaryx Therapeutics believes there is an opportunity to seek accelerated approval for its most advanced drug candidate, PLX-200, for the treatment of Classic Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2) and Juvenile Neuronal Ceroid Lipofuscinosis (CLN3). If successful, this could lead to the company's first commercial product and a significant revenue stream within the specified timeframe.
- Successful Advancement of PLX-200 through the SOTERIA Basket Trial Leading to Registrable Studies for Multiple Lysosomal Storage Disorders (LSDs): The SOTERIA trial, a Phase 2 proof-of-concept basket trial for PLX-200, is expected to initiate in the first half of 2026 and targets several LSDs, including CLN2, CLN3, Krabbe disease, and Sandhoff disease. Positive data readouts from this multi-indication study are anticipated to provide a clear pathway for each of the four indications towards potentially registrable trials, thereby expanding the potential market reach and future revenue streams for PLX-200 beyond initial accelerated approvals.
- Potential for Strategic Partnerships or Licensing Agreements Driven by Positive Clinical Data for PLX-200: As a clinical-stage biotechnology company, positive clinical data, especially from the SOTERIA trial, could make PLX-200 and Polaryx Therapeutics an attractive candidate for strategic collaborations or licensing agreements. Such partnerships could provide upfront payments, milestone achievements, and royalties, contributing to revenue growth as the drug progresses towards commercialization across various LSD indications.
AI Analysis | Feedback
Share Issuance
- Polaryx Therapeutics significantly increased its Additional Paid In Capital, a key indicator of funds raised through equity offerings. This figure grew from $61.6 million in December 2023 to $95.3 million in December 2024, representing an issuance of $33.7 million in shares during that period.
- The company continued to issue shares, with Additional Paid In Capital increasing by another $8.1 million from December 2024 to $103.4 million by the last reported quarter of 2025.
- Overall, Polaryx Therapeutics issued approximately $41.8 million in shares between December 2023 and the end of 2025.
Inbound Investments
- Significant inbound investment has occurred through equity financing, evidenced by the increase in Additional Paid In Capital by $41.8 million from December 2023 to the end of 2025.
- A Schedule 13D filing in February 2026 indicated that major holders collectively reported 48% ownership in Polaryx Therapeutics, signifying substantial institutional investment in the company.
Capital Expenditures
- As a clinical-stage biotechnology company primarily focused on research and development, Polaryx Therapeutics' capital expenditures are likely directed towards laboratory equipment and facilities to support its drug pipeline development.
Trade Ideas
Select ideas related to PLYX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 11.79 |
| Mkt Cap | 3.2 |
| Rev LTM | 138 |
| Op Inc LTM | -6 |
| FCF LTM | -3 |
| FCF 3Y Avg | -35 |
| CFO LTM | -3 |
| CFO 3Y Avg | -35 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 62.3% |
| Rev Chg 3Y Avg | 25.1% |
| Rev Chg Q | 33.4% |
| QoQ Delta Rev Chg LTM | 5.8% |
| Op Mgn LTM | 0.7% |
| Op Mgn 3Y Avg | -93.3% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 1.9% |
| CFO/Rev 3Y Avg | -72.9% |
| FCF/Rev LTM | 1.2% |
| FCF/Rev 3Y Avg | -73.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.2 |
| P/S | 4.0 |
| P/EBIT | 5.5 |
| P/E | -2.1 |
| P/CFO | -3.2 |
| Total Yield | -0.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -9.8% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -6.0% |
| 3M Rtn | -4.3% |
| 6M Rtn | -2.9% |
| 12M Rtn | 7.9% |
| 3Y Rtn | -30.1% |
| 1M Excs Rtn | 2.4% |
| 3M Excs Rtn | 3.7% |
| 6M Excs Rtn | 3.1% |
| 12M Excs Rtn | -5.8% |
| 3Y Excs Rtn | -91.5% |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Landis, G. Michael | Chief Financial Officer | Direct | Buy | 2202026 | 2.79 | 2,867 | 7,991 | 636,086 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.